Tsumura & Co
4540.TPharmaceutical
Filed as TSUMURA & CO. (2022-06–2026-06)
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥192.6bn | ¥181.1bn | ¥150.8bn | ¥140.0bn | ¥129.5bn | ¥116.4bn |
| Operating income | ¥35.2bn | ¥40.1bn | ¥20.0bn | ¥20.9bn | ¥22.4bn | ¥19.4bn |
| Ordinary income | ¥40.0bn | ¥42.4bn | ¥23.5bn | ¥23.5bn | ¥25.9bn | ¥20.9bn |
| Net income (owners) | ¥28.1bn | ¥32.4bn | ¥16.7bn | ¥16.5bn | ¥18.8bn | ¥15.3bn |
| Total assets | ¥592.8bn | ¥464.4bn | ¥428.3bn | ¥396.8bn | ¥351.0bn | ¥319.1bn |
| Net assets / equity | ¥371.6bn | ¥330.1bn | ¥295.4bn | ¥272.2bn | ¥258.1bn | ¥233.2bn |
| Operating cash flow | ¥24.7bn | ¥33.8bn | ¥5.6bn | ¥16.5bn | ¥21.3bn | ¥16.1bn |
| EPS (basic) | ¥376.28 | ¥427.15 | ¥219.83 | ¥215.63 | ¥246.21 | ¥200.4 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 197 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 67 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 197 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 67 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 197 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 69 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 69 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 67 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 197 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 69 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 69 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 67 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 197 figures · EDINET |
21 more reports are still being processed.